2.1.1 USFDA guidelines for ANDA: This guidance is intended to assist applicants in preparing abbreviated new drug applications 18 (ANDAs) for submission to the Food and Drug Administration (FDA) under section 505(j) of the 19 Federal Food, Drug and Cosmetic Act (the FD&C Act) (21 U.S.C. 355(j)). This guidance details 20 the information to be provided in each section of the Common Technical Document (CTD) 21 format for human pharmaceutical product applications and identifies supporting guidance 22 documents and recommendations issued by FDA to assist in preparing the submission. This 23 guidance does not address the fee structure or payment of obligations under the Generic Drug 24 User Fee Amendments (GDUFA)[32 ]and does not address the submission …show more content…
Nitin Kashyap, et al, (2013). They studied drug filing and different aspects of obtaining United States Food & Drug Administration (USFDA) and European Medicines Agency (EMA) approval for a drug in order to get a Marketing Authorization in US & Europe and their effective role in improving the standards laid down by them. All new / generic drug products must be approved by the respective regulatory agency governing the respective market before a particular product can be introduced into the market. By law, all new drugs must first be shown to be safe and effective before they can be approved by the respective regulatory agency for marketing. USFDA is the regulatory agency which is responsible for safety regulation of the food and drug products in US. EMA is the regulatory agency/ decentralized body which is responsible for safety regulation of the food and drug products in …show more content…
For proving patent infringement it requires merely showing the court on market products and comparing it to patent at issue. US law, however, provides for a different kind of infringement i.e. potential future infringement by generic pharmaceutical which does not yet exist because it needs approval to come in market.[34] 2.2.5 Bhardwaj S et al (2011) authors described the common technical requirements regulated by ICH as CTD in major pharmaceutical market in the US and EU. It consists of five modules, but differs in the information as per the regional requirements. They explained the difference between registration requirements through CTD and Electronic Common Technical Document (eCTD). 2.2.6 Sharma D et al (2011) in brief authors explained about the dossier submission in Europe and US. It is a file document based on the requirements of the approval of drug product and it is necessary to submit in the form of CTD. CTD consist of 5 modules and after compilation submitted to respective regulatory authorities. For US three copies are required and one copy for